Brokerages predict that Aterian, Inc. (NASDAQ:ATER – Get Rating) will report sales of $45.37 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Aterian’s earnings. The lowest sales estimate is $40.05 million and the highest is $50.70 million. Aterian reported sales of $48.14 million in the same quarter last year, which indicates a negative year-over-year growth rate of 5.8%. The business is scheduled to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Aterian will report full-year sales of $264.21 million for the current financial year, with estimates ranging from $262.53 million to $265.90 million. For the next fiscal year, analysts forecast that the firm will report sales of $317.59 million, with estimates ranging from $300.90 million to $334.28 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Aterian.
Aterian (NASDAQ:ATER – Get Rating) last announced its quarterly earnings data on Tuesday, March 8th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. Aterian had a negative net margin of 94.74% and a negative return on equity of 42.93%. During the same quarter in the prior year, the firm posted ($0.33) earnings per share.
NASDAQ ATER opened at $5.31 on Wednesday. Aterian has a 52 week low of $2.10 and a 52 week high of $26.18. The stock has a market cap of $329.72 million, a price-to-earnings ratio of -0.70 and a beta of 2.71. The company has a 50-day moving average price of $3.37 and a two-hundred day moving average price of $4.38.
In related news, insider Yaniv Zion Sarig sold 166,127 shares of the stock in a transaction that occurred on Wednesday, March 23rd. The shares were sold at an average price of $2.68, for a total transaction of $445,220.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.80% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP lifted its position in shares of Aterian by 327.3% in the 3rd quarter. Hudson Bay Capital Management LP now owns 3,347,184 shares of the company’s stock valued at $34,709,000 after acquiring an additional 2,563,883 shares in the last quarter. Morgan Stanley purchased a new stake in shares of Aterian in the 2nd quarter valued at approximately $5,227,000. BlackRock Inc. lifted its position in shares of Aterian by 24.7% in the 3rd quarter. BlackRock Inc. now owns 1,547,874 shares of the company’s stock valued at $16,762,000 after acquiring an additional 306,539 shares in the last quarter. Geode Capital Management LLC increased its stake in Aterian by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 584,904 shares of the company’s stock valued at $2,403,000 after buying an additional 172,652 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in Aterian in the 4th quarter valued at approximately $572,000. 24.29% of the stock is owned by institutional investors and hedge funds.
Aterian Company Profile (Get Rating)
Aterian, Inc, together with its subsidiaries, operates as a technology-enabled consumer products company in North America and internationally. The company provides Artificial Intelligence Marketplace e-Commerce Engine, a software technology platform, which uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products.
Recommended Stories
- Get a free copy of the StockNews.com research report on Aterian (ATER)
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
- Whirlpool Is A Steal At These Prices
- Kimberly-Clark Pops On Successful Price Pass-Through
Get a free copy of the Zacks research report on Aterian (ATER)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aterian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aterian and related companies with MarketBeat.com's FREE daily email newsletter.